Has Philip Khoury, MD received payments from drug or device companies?

Yes. Drug and device makers reported $285 in general payments to Philip Khoury, MD across 15 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Philip Khoury, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Philip Khoury, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Philip Khoury, MD

Psychiatry · Kansas City, MONPI 1710974076

Payments from drug & device makers

$285in general payments, 2019–2025

Across 15 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lundbeck LLC$68
Shire North American Group Inc$48
Otsuka America Pharmaceutical, Inc.$42
Sunovion Pharmaceuticals Inc.$32
Takeda Pharmaceuticals U.S.A., Inc.$24
Johnson & Johnson$22
plus $49 from 3 others

What the payments were for

Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lundbeck LLC	3	$68
Shire North American Group Inc	3	$48
Otsuka America Pharmaceutical, Inc.	2	$42
Sunovion Pharmaceuticals Inc.	2	$32
Takeda Pharmaceuticals U.S.A., Inc.	1	$24
Johnson & Johnson	1	$22
Alkermes, Inc.	1	$21
Acadia Pharmaceuticals Inc	1	$16
Neurocrine Biosciences, Inc.	1	$12

How this compares

$285 in reported general payments places this provider in the 50th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri →

Medicare billing

Part B allowed, 2024

$36,340

Medicare patients

Services billed

418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Quetiapine Fumarate	19	$1,366
Aripiprazole	28	$911
Divalproex Sodium	46	$776
Hydroxyzine Hcl	29	$450
Gabapentin	27	$312
Mirtazapine	12	$249
Fluoxetine Hcl	29	$248
Buspirone Hcl	22	$221
Trazodone Hcl	40	$199
Duloxetine Hcl	11	$108
Prazosin Hcl	11	$91
Sertraline Hcl	20	$73

Paid to pharmacies, not to this prescriber.

Other psychiatry in Kansas City

Brian BarashKansas City$857K
Mark CannonKansas City$19K
Syed KarimKansas City$17K
Gregory MattingleySaint Charles$8.2M
Junaid SyedSaint Louis$8M
Eric CarbonellFestus$5.4M
Ricky MofsenSaint Louis$4.9M
Charles ConwaySaint Louis$3.8M
Mohd MalikSaint Louis$2.8M
Franco SicuroOlivette$2.3M

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →